Coliseum Capital Dumps Some More Accuride Corporation (ACW) Shares; Increases Stake In Advanced Emissions Solutions, Inc. (ADES)

Christopher Shackelton and Adam Gray, the managers of Coliseum Capital, are still offloading Accuride Corporation (NYSE:ACW) shares as reported in a recent Form 4 filing with the Securities and Exchange Commission. In the latest round, 232,595 shares were disposed of in three transactions at prices between $5.14 and $5.38 apiece. As a result, Coliseum Capital now holds 7.35 million shares of Accuride Corporation (NYSE:ACW).

Accuride Logo

In another filing with the SEC, Coliseum revealed the addition of some 286,744 shares of Advanced Emissions Solutions, Inc. (NASDAQ:ADES) to its equity portfolio. Following this move, the fund’s stake in the company has risen to 1.71 million shares, which account for approximately 7.9% of the company’s common stock.

Chuck Royce is still bullish on Accuride Corporation (NYSE:ACW) and has continued to grow his investment in the company during the first quarter of 2014. In its latest 13F filing, Royce & Associates reported ownership of 1.8 million shares, up 32% for the quarter. James Dinan is also keeping tabs on this company, with his fund, York Capital Management, reporting a position that amasses exactly 750,000 shares. Peter Schliemann, on the other hand, has decided to reduce his fund’s exposure to Accuride Corporation (NYSE:ACW) and has trimmed his stake by 5% to 2.39 million shares.

Advanced Emissions Solutions, Inc. (NASDAQ:ADES) has also caught the attention of hedge fund guru, Jim Simons. His fund, Renaissance Technologies, has boosted its stake by 99% to amass 416,400 shares, as reported in its latest 13F filing. Michael Barnes and Arif Inayatullah, the managers of Tricadia Capital Management, are also bullish on this stock and have increased their holding by 156% to a little under 655,500 shares. Moab Capital Partners stake in Advanced Emissions Solutions, Inc. (NASDAQ:ADES) has surged by 192% during the first quarter of 2014, signaling the bullishness of its managers, Michael M. Rothenberg and David Sackler. Moab Capital reported the holding of approximately 724,500 shares in its latest 13F filing.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!